◦c with anti dpp4  (Cell Signaling Technology Inc)

Journal: International Journal of Molecular Medicine

Article Title: Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis

doi: 10.3892/ijmm.2025.5592

Figure Lengend Snippet: Serial changes of serum levels of BUN, creatinine, DPP4 and GLP-1 and R Up/c . Circulating levels of (A) BUN, (B) creatinine, (C) DPP4 and (D) GLP-1, and (E) R Up/c at baseline. Circulating levels of (F) BUN, (G) creatinine, (H) DPP4 and (I) GLP-1, and (J) R Up/c at day 14 after CKD induction. Circulating levels of (K) BUN, (L) creatinine, (M) DPP4 and (N) GLP-1, and (O) R Up/c at day 35 after CKD induction. Circulating levels of (P) BUN, (Q) creatinine, (R) DPP4 and (S) GLP-1, and (T) R Up/c at day 42 after CKD induction. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni's multiple comparisons post hoc test (n=6/group). # P<0.05, ## P<0.01 vs. SC; * P<0.05 vs. CKD; ns, not significant. BUN, blood urea nitrogen; CG, chlorhexidine gluconate; CKD, chronic kidney disease; DPP4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; R uP/uC , ratio of urine protein/urine creatinine; SC, sham control.

Article Snippet: Primary antibodies used in the western blot analysis included: NOX-1 (1:1,000; cat. no. SAB4200097; Sigma-Aldrich; Merck KGaA), NOX-2 (1:1,000; cat. no. MABS2195; Sigma-Aldrich; Merck KGaA), TNF-α (1:1,000; cat. no. 3707; Cell Signaling Technology, Inc.), IL-1α (1:1,000; cat. no. 84618; Cell Signaling Technology, Inc.), MMP-9 (1:1,000; cat. no. ab76003; Abcam), DPP4 (1:1,000; cat. no. ARP63319_P050; Aviva Systems Biology), phosphorylated (p)-Smad3 (1:1,000; cat. no. 9520; Cell Signaling Technology, Inc.), Smad3 (1:1,000; cat. no. 9513; Cell Signaling Technology, Inc.), TGF-β (1:3,000; cat. no. ab215715; Abcam), GLP-1 (1:1,000; cat. no. ab108443; Abcam), GLP-1R (1:1,000; cat. no. ab218532; Abcam), nuclear factor erythroid 2-related factor 2 (Nrf2; 1:1,000; cat. no. ab62352; Abcam), NAD(P)H quinone oxidoreductase 1 (NQO-1; 1:1,000; cat. no. ab80588; Abcam), Snail (1:1,000; cat. no. 3879; Cell Signaling Technology, Inc.), von Willebrand factor (vWF; 1:1,000; cat. no. ab154193; Abcam), VEGF (1:1,000; cat. no. ab214424; Abcam), α-smooth muscle actin (α-SMA; 1:6,000; cat. no. A2547; Sigma-Aldrich; Merck KGaA), vimentin (1:1,000; cat. no. 5741; Cell Signaling Technology, Inc.), β-catenin (1:1,000; cat. no. 8480; Cell Signaling Technology, Inc.), fibronectin (1:1,000 cat. no. ab2413; Abcam), collagen I (1:1,000; cat. no. C2456; Sigma-Aldrich; Merck KGaA), N-cadherin (1:1,000; cat. no. 13116; Cell signaling Technology, Inc.), TLR-2 (1:4,000; cat. no. ab213676; Abcam), TLR-4 (1:4,000; cat. no. NB100-56566; Novus Biologicals, LLC; Bio-Techne), NF-κB (1:1,000; cat. no. 8242; Cell Signaling Technology, Inc.), p-NF-κB (1:1,000; cat. no. 3033; Cell Signaling Technology, Inc.), CD31 (1:1,000; cat. no. 77699; Cell Signaling Technology, Inc.) and β-actin (1:10,000; cat. no. A5441; MilliporeSigma).

Techniques: Control

Journal: International Journal of Molecular Medicine

Article Title: Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis

doi: 10.3892/ijmm.2025.5592

Figure Lengend Snippet: Protein expression levels of biomarkers of oxidative stress, inflammation and angiogenesis, as well as DPP4, GLP-1R and antioxidants in the peritonium by day 42 after CKD induction. (A) Protein expression levels were detected by western blot analysis. Semi-quantification of (B) NOX-1, (C) vWF, (D) GLP-1R, (E) NOX-2, (F) TNF-α, (G) Nrf2, (H) NQO-1, (I) p-NF-κB/NF-κB, (J) CD31, (K) DPP4 and (L) VEGF. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni's multiple comparisons post hoc test (n=6/group). # P<0.05, ## P<0.01 vs. SC; * P<0.05 vs. CKD. CG, chlorhexidine gluconate; CKD, chronic kidney disease; DPP4, dipeptidyl peptidase 4; GLP-1R, glucagon-like peptide 1 receptor; NQO-1, NAD(P)H-quinone oxidoreduc-tase 1; Nrf2, nuclear factor erythroid 2-related factor 2; p-, phosphorylated; SC, sham control; vWF, von Willebrand factor.

Article Snippet: Primary antibodies used in the western blot analysis included: NOX-1 (1:1,000; cat. no. SAB4200097; Sigma-Aldrich; Merck KGaA), NOX-2 (1:1,000; cat. no. MABS2195; Sigma-Aldrich; Merck KGaA), TNF-α (1:1,000; cat. no. 3707; Cell Signaling Technology, Inc.), IL-1α (1:1,000; cat. no. 84618; Cell Signaling Technology, Inc.), MMP-9 (1:1,000; cat. no. ab76003; Abcam), DPP4 (1:1,000; cat. no. ARP63319_P050; Aviva Systems Biology), phosphorylated (p)-Smad3 (1:1,000; cat. no. 9520; Cell Signaling Technology, Inc.), Smad3 (1:1,000; cat. no. 9513; Cell Signaling Technology, Inc.), TGF-β (1:3,000; cat. no. ab215715; Abcam), GLP-1 (1:1,000; cat. no. ab108443; Abcam), GLP-1R (1:1,000; cat. no. ab218532; Abcam), nuclear factor erythroid 2-related factor 2 (Nrf2; 1:1,000; cat. no. ab62352; Abcam), NAD(P)H quinone oxidoreductase 1 (NQO-1; 1:1,000; cat. no. ab80588; Abcam), Snail (1:1,000; cat. no. 3879; Cell Signaling Technology, Inc.), von Willebrand factor (vWF; 1:1,000; cat. no. ab154193; Abcam), VEGF (1:1,000; cat. no. ab214424; Abcam), α-smooth muscle actin (α-SMA; 1:6,000; cat. no. A2547; Sigma-Aldrich; Merck KGaA), vimentin (1:1,000; cat. no. 5741; Cell Signaling Technology, Inc.), β-catenin (1:1,000; cat. no. 8480; Cell Signaling Technology, Inc.), fibronectin (1:1,000 cat. no. ab2413; Abcam), collagen I (1:1,000; cat. no. C2456; Sigma-Aldrich; Merck KGaA), N-cadherin (1:1,000; cat. no. 13116; Cell signaling Technology, Inc.), TLR-2 (1:4,000; cat. no. ab213676; Abcam), TLR-4 (1:4,000; cat. no. NB100-56566; Novus Biologicals, LLC; Bio-Techne), NF-κB (1:1,000; cat. no. 8242; Cell Signaling Technology, Inc.), p-NF-κB (1:1,000; cat. no. 3033; Cell Signaling Technology, Inc.), CD31 (1:1,000; cat. no. 77699; Cell Signaling Technology, Inc.) and β-actin (1:10,000; cat. no. A5441; MilliporeSigma).

Techniques: Expressing, Western Blot, Control

Journal: International Journal of Molecular Medicine

Article Title: Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis

doi: 10.3892/ijmm.2025.5592

Figure Lengend Snippet: LPS induces peritoneal damaged by day 5 of treatment. Circulating levels of (A) GLP-1 and (B) DPP4 at baseline. Circulating levels of (C) GLP-1 and (D) DPP4 at day 5. Abdominal levels of (E) GLP-1 and (F) DPP4 at day 5. Circulating levels of the indicator of peritoneal permeability FITC-dextran (G) 10, (H) 20 and (I) 30 min after LPS treatment. Flow cytometric analysis of the number of (J) CD11b/c + , (K) MPO + anf (L) Ly6G + cells in circulation. Flow cytometric analysis of the number of (M) CD11b/c + , (N) MPO + cells and (O) Ly6G + cells in the abdominal fluid. All statistical analyses were performed by one-way ANOVA, followed by Bonferroni's multiple comparisons post hoc test (n=6/group). # P<0.05 vs. SC; * P<0.05 vs. LPS. DPP4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; LPS, lipopolysaccharide; MPO, myeloperoxidase; SC, sham control.

Article Snippet: Primary antibodies used in the western blot analysis included: NOX-1 (1:1,000; cat. no. SAB4200097; Sigma-Aldrich; Merck KGaA), NOX-2 (1:1,000; cat. no. MABS2195; Sigma-Aldrich; Merck KGaA), TNF-α (1:1,000; cat. no. 3707; Cell Signaling Technology, Inc.), IL-1α (1:1,000; cat. no. 84618; Cell Signaling Technology, Inc.), MMP-9 (1:1,000; cat. no. ab76003; Abcam), DPP4 (1:1,000; cat. no. ARP63319_P050; Aviva Systems Biology), phosphorylated (p)-Smad3 (1:1,000; cat. no. 9520; Cell Signaling Technology, Inc.), Smad3 (1:1,000; cat. no. 9513; Cell Signaling Technology, Inc.), TGF-β (1:3,000; cat. no. ab215715; Abcam), GLP-1 (1:1,000; cat. no. ab108443; Abcam), GLP-1R (1:1,000; cat. no. ab218532; Abcam), nuclear factor erythroid 2-related factor 2 (Nrf2; 1:1,000; cat. no. ab62352; Abcam), NAD(P)H quinone oxidoreductase 1 (NQO-1; 1:1,000; cat. no. ab80588; Abcam), Snail (1:1,000; cat. no. 3879; Cell Signaling Technology, Inc.), von Willebrand factor (vWF; 1:1,000; cat. no. ab154193; Abcam), VEGF (1:1,000; cat. no. ab214424; Abcam), α-smooth muscle actin (α-SMA; 1:6,000; cat. no. A2547; Sigma-Aldrich; Merck KGaA), vimentin (1:1,000; cat. no. 5741; Cell Signaling Technology, Inc.), β-catenin (1:1,000; cat. no. 8480; Cell Signaling Technology, Inc.), fibronectin (1:1,000 cat. no. ab2413; Abcam), collagen I (1:1,000; cat. no. C2456; Sigma-Aldrich; Merck KGaA), N-cadherin (1:1,000; cat. no. 13116; Cell signaling Technology, Inc.), TLR-2 (1:4,000; cat. no. ab213676; Abcam), TLR-4 (1:4,000; cat. no. NB100-56566; Novus Biologicals, LLC; Bio-Techne), NF-κB (1:1,000; cat. no. 8242; Cell Signaling Technology, Inc.), p-NF-κB (1:1,000; cat. no. 3033; Cell Signaling Technology, Inc.), CD31 (1:1,000; cat. no. 77699; Cell Signaling Technology, Inc.) and β-actin (1:10,000; cat. no. A5441; MilliporeSigma).

Techniques: Permeability, Control

Journal: International Journal of Molecular Medicine

Article Title: Dulaglutide markedly prevents peritoneal fibrosis in a rodent model of chronic kidney disease: Insights into the pathogenesis

doi: 10.3892/ijmm.2025.5592

Figure Lengend Snippet: Schematic diagram of the proposed underlying mechanims of dulaglutide treatment of peritoneal fibrosis and PD failure. CKD, chronic kidney disease; DPP4, dipeptidyl peptidase 4; EMT, epithelial-mesenchymal transion; GLP-1, glucagon-like peptide 1; GLP-1R, GLP-1 receptor; LPS, lipopolysac-charide; NQO-1, NAD(P)H-quinone oxidoreductase 1; Nrf2, nuclear factor erythroid 2-related factor 2; PD, pertoneal dialysis.

Article Snippet: Primary antibodies used in the western blot analysis included: NOX-1 (1:1,000; cat. no. SAB4200097; Sigma-Aldrich; Merck KGaA), NOX-2 (1:1,000; cat. no. MABS2195; Sigma-Aldrich; Merck KGaA), TNF-α (1:1,000; cat. no. 3707; Cell Signaling Technology, Inc.), IL-1α (1:1,000; cat. no. 84618; Cell Signaling Technology, Inc.), MMP-9 (1:1,000; cat. no. ab76003; Abcam), DPP4 (1:1,000; cat. no. ARP63319_P050; Aviva Systems Biology), phosphorylated (p)-Smad3 (1:1,000; cat. no. 9520; Cell Signaling Technology, Inc.), Smad3 (1:1,000; cat. no. 9513; Cell Signaling Technology, Inc.), TGF-β (1:3,000; cat. no. ab215715; Abcam), GLP-1 (1:1,000; cat. no. ab108443; Abcam), GLP-1R (1:1,000; cat. no. ab218532; Abcam), nuclear factor erythroid 2-related factor 2 (Nrf2; 1:1,000; cat. no. ab62352; Abcam), NAD(P)H quinone oxidoreductase 1 (NQO-1; 1:1,000; cat. no. ab80588; Abcam), Snail (1:1,000; cat. no. 3879; Cell Signaling Technology, Inc.), von Willebrand factor (vWF; 1:1,000; cat. no. ab154193; Abcam), VEGF (1:1,000; cat. no. ab214424; Abcam), α-smooth muscle actin (α-SMA; 1:6,000; cat. no. A2547; Sigma-Aldrich; Merck KGaA), vimentin (1:1,000; cat. no. 5741; Cell Signaling Technology, Inc.), β-catenin (1:1,000; cat. no. 8480; Cell Signaling Technology, Inc.), fibronectin (1:1,000 cat. no. ab2413; Abcam), collagen I (1:1,000; cat. no. C2456; Sigma-Aldrich; Merck KGaA), N-cadherin (1:1,000; cat. no. 13116; Cell signaling Technology, Inc.), TLR-2 (1:4,000; cat. no. ab213676; Abcam), TLR-4 (1:4,000; cat. no. NB100-56566; Novus Biologicals, LLC; Bio-Techne), NF-κB (1:1,000; cat. no. 8242; Cell Signaling Technology, Inc.), p-NF-κB (1:1,000; cat. no. 3033; Cell Signaling Technology, Inc.), CD31 (1:1,000; cat. no. 77699; Cell Signaling Technology, Inc.) and β-actin (1:10,000; cat. no. A5441; MilliporeSigma).

Techniques: